Analysts have recently adjusted their ratings and price targets for Progyny, Inc. (NASDAQ: PGNY), as significant insider transactions have taken place. On November 13, 2023, CEO Peter Anevski acquired 79,500 shares of the company, purchasing them at an average price of $24.29 per share. This transaction totaled approximately $1.93 million and increased his ownership stake by 13.23%. Following this acquisition, Anevski now holds a total of 680,251 shares, valued at around $16.52 million.
In contrast, Chief Financial Officer Mark S. Livingston sold 21,303 shares on November 17, 2023. These shares were sold at an average price of $25.50, bringing in approximately $543,227. After this sale, Livingston’s holdings decreased by 30.58%, leaving him with 48,358 shares, valued at about $1.23 million.
Recent filings with the U.S. Securities and Exchange Commission (SEC) provide further details on these transactions. Over the last quarter, insiders have sold a total of 22,046 shares valued at approximately $561,691. Currently, insiders hold 9.40% of Progyny’s stock.
Progyny, known for its innovative Smart Cycle® benefit, offers a comprehensive package that integrates clinical, emotional, and logistical support for its users. This strategic approach to reproductive health has garnered attention, contributing to the company’s appeal among investors.
The market continues to monitor these developments closely, as insider trading can often signal confidence or concerns regarding a company’s future. As analysts refine their assessments, Progyny remains a focal point for those interested in the evolving landscape of healthcare benefits.
For ongoing updates, investors can subscribe to a daily newsletter from MarketBeat, which provides concise summaries of the latest news and ratings related to Progyny and similar companies.
